Cargando…
Patient perspectives on molecular tumor profiling: “Why wouldn’t you?”
AIM: This study explored the attitudes of patients with advanced cancer towards MTP and return of results, prior to undergoing genomic testing within a research program. METHODS: Participants were recruited as part of the longitudinal PiGeOn (Psychosocial Issues in Genomics in Oncology) study involv...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670204/ https://www.ncbi.nlm.nih.gov/pubmed/31366375 http://dx.doi.org/10.1186/s12885-019-5920-x |
_version_ | 1783440516759683072 |
---|---|
author | Best, Megan C. Bartley, Nicole Jacobs, Chris Juraskova, Ilona Goldstein, David Newson, Ainsley J. Savard, Jacqueline Meiser, Bettina Ballinger, Mandy Napier, Christine Thomas, David Biesecker, Barbara Butow, Phyllis |
author_facet | Best, Megan C. Bartley, Nicole Jacobs, Chris Juraskova, Ilona Goldstein, David Newson, Ainsley J. Savard, Jacqueline Meiser, Bettina Ballinger, Mandy Napier, Christine Thomas, David Biesecker, Barbara Butow, Phyllis |
author_sort | Best, Megan C. |
collection | PubMed |
description | AIM: This study explored the attitudes of patients with advanced cancer towards MTP and return of results, prior to undergoing genomic testing within a research program. METHODS: Participants were recruited as part of the longitudinal PiGeOn (Psychosocial Issues in Genomics in Oncology) study involving patients with advanced/metastatic solid cancer who had exhausted therapeutic options and who were offered MTP in order to identify cognate therapies. Twenty patients, selected by purposive sampling, were interviewed around the time they gave consent to MTP. Interviews were audio recorded, transcribed and analysed using thematic analysis. Themes identified in the transcripts were cross-validated via qualitative responses to the PiGeOn study survey (n = 569; 63%). RESULTS: All interviewed participants gave consent to MTP without reservation. Three themes were identified and further supported via the survey responses: (1) Obvious agreement to participate, primarily because of desire for new treatments and altruism. (2) The black box – while participant knowledge of genomics was generally poor, faith in their oncologists and the scientific process encouraged them to proceed with testing; and (3) Survival is the priority – receiving treatment to prolong life was the priority for all participants, and other issues such as identification of a germline variant were generally seen as ancillary. CONCLUSION: Having advanced cancer seemed to abrogate any potential concerns about MTP. Participants valued the research for varied reasons, but this was secondary to their priority to survive. While no negative attitudes toward MTP emerged, limitations in understanding of genomics were evident. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5920-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6670204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66702042019-08-06 Patient perspectives on molecular tumor profiling: “Why wouldn’t you?” Best, Megan C. Bartley, Nicole Jacobs, Chris Juraskova, Ilona Goldstein, David Newson, Ainsley J. Savard, Jacqueline Meiser, Bettina Ballinger, Mandy Napier, Christine Thomas, David Biesecker, Barbara Butow, Phyllis BMC Cancer Research Article AIM: This study explored the attitudes of patients with advanced cancer towards MTP and return of results, prior to undergoing genomic testing within a research program. METHODS: Participants were recruited as part of the longitudinal PiGeOn (Psychosocial Issues in Genomics in Oncology) study involving patients with advanced/metastatic solid cancer who had exhausted therapeutic options and who were offered MTP in order to identify cognate therapies. Twenty patients, selected by purposive sampling, were interviewed around the time they gave consent to MTP. Interviews were audio recorded, transcribed and analysed using thematic analysis. Themes identified in the transcripts were cross-validated via qualitative responses to the PiGeOn study survey (n = 569; 63%). RESULTS: All interviewed participants gave consent to MTP without reservation. Three themes were identified and further supported via the survey responses: (1) Obvious agreement to participate, primarily because of desire for new treatments and altruism. (2) The black box – while participant knowledge of genomics was generally poor, faith in their oncologists and the scientific process encouraged them to proceed with testing; and (3) Survival is the priority – receiving treatment to prolong life was the priority for all participants, and other issues such as identification of a germline variant were generally seen as ancillary. CONCLUSION: Having advanced cancer seemed to abrogate any potential concerns about MTP. Participants valued the research for varied reasons, but this was secondary to their priority to survive. While no negative attitudes toward MTP emerged, limitations in understanding of genomics were evident. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5920-x) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-31 /pmc/articles/PMC6670204/ /pubmed/31366375 http://dx.doi.org/10.1186/s12885-019-5920-x Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Best, Megan C. Bartley, Nicole Jacobs, Chris Juraskova, Ilona Goldstein, David Newson, Ainsley J. Savard, Jacqueline Meiser, Bettina Ballinger, Mandy Napier, Christine Thomas, David Biesecker, Barbara Butow, Phyllis Patient perspectives on molecular tumor profiling: “Why wouldn’t you?” |
title | Patient perspectives on molecular tumor profiling: “Why wouldn’t you?” |
title_full | Patient perspectives on molecular tumor profiling: “Why wouldn’t you?” |
title_fullStr | Patient perspectives on molecular tumor profiling: “Why wouldn’t you?” |
title_full_unstemmed | Patient perspectives on molecular tumor profiling: “Why wouldn’t you?” |
title_short | Patient perspectives on molecular tumor profiling: “Why wouldn’t you?” |
title_sort | patient perspectives on molecular tumor profiling: “why wouldn’t you?” |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670204/ https://www.ncbi.nlm.nih.gov/pubmed/31366375 http://dx.doi.org/10.1186/s12885-019-5920-x |
work_keys_str_mv | AT bestmeganc patientperspectivesonmoleculartumorprofilingwhywouldntyou AT bartleynicole patientperspectivesonmoleculartumorprofilingwhywouldntyou AT jacobschris patientperspectivesonmoleculartumorprofilingwhywouldntyou AT juraskovailona patientperspectivesonmoleculartumorprofilingwhywouldntyou AT goldsteindavid patientperspectivesonmoleculartumorprofilingwhywouldntyou AT newsonainsleyj patientperspectivesonmoleculartumorprofilingwhywouldntyou AT savardjacqueline patientperspectivesonmoleculartumorprofilingwhywouldntyou AT meiserbettina patientperspectivesonmoleculartumorprofilingwhywouldntyou AT ballingermandy patientperspectivesonmoleculartumorprofilingwhywouldntyou AT napierchristine patientperspectivesonmoleculartumorprofilingwhywouldntyou AT thomasdavid patientperspectivesonmoleculartumorprofilingwhywouldntyou AT bieseckerbarbara patientperspectivesonmoleculartumorprofilingwhywouldntyou AT butowphyllis patientperspectivesonmoleculartumorprofilingwhywouldntyou AT patientperspectivesonmoleculartumorprofilingwhywouldntyou |